For further details see:
ACADIA Pharma net loss widens ~70% but reiterates 2022 guidanceFor further details see:
ACADIA Pharma net loss widens ~70% but reiterates 2022 guidanceMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
ACADIA Pharmaceuticals Inc. Company Name:
ACAD Stock Symbol:
Market:
ACADIA Pharmaceuticals Inc. Website:
-- Continued Improvements in RSBQ and CGI-I scores seen with long-term DAYBUE treatment in Phase 3 LAVENDER™ and LILAC studies -- DAYBUE safety profile was consistent with findings from the LAVENDER trial Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the...
2024-06-26 17:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for ACAD on June 26, 2024 04:09PM ET. The previous analyst recommendation was Buy. ACAD was trading at $15.5 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...
2024-06-26 17:00:07 ET Keith Tapper from BMO Capital issued a price target of $31.00 for ACAD on 2024-06-26 16:09:00. The adjusted price target was set to $31.00. At the time of the announcement, ACAD was trading at $15.5. The overall price target consensus is at $26.25 ...